Skip to main content

Advertisement

SpringerLink
Log in

Adjuvant HIPEC in Colorectal Cancer

  • Adjuvant Therapy for Colon Cancers (AB Benson III and A de Gramont, Section Editors)
  • Published:
Current Colorectal Cancer Reports

Abstract

Peritoneal carcinomatosis (PC) of colorectal origin has historically been regarded as fatal, with worse prognosis than other metastatic manifestations of the same origin. During the last three decades, complete cytoreductive surgery associated with adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) has led to improvement of outcome, with long-term survival being achieved for selected patients. This treatment is on the verge of becoming the standard of care for this metastatic disease. In this paper we review the rationale for HIPEC, the results obtained, and define its current indications. Future developments of HIPEC are also discussed, mainly its use as a prophylactic approach to prevent the occurrence of PC in high-risk patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Koppe MJ, Boerman OC, Oyen WJ, Bleichrodt RP. Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann Surg. 2006;243:212–22.

    Article  PubMed Central  PubMed  Google Scholar 

  2. Klaver YL, Lemmens VE, Nienhuijs SW, Luyer MD, de Hingh IH. Peritoneal carcinomatosis of colorectal origin: incidence, prognosis and treatment options. World J Gastroenterol. 2012;18:5489–94.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  3. Cao C, Yan TD, Black D, et al. A systematic review and meta-analysis of cytoreductive surgery with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol. 2009;16:2152–65.

    Article  PubMed  Google Scholar 

  4. Elias D, Gilly F, Boutitie F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010;28:63–8. By presenting mature multicentre data on such a large number of patients, this report is a milestone on the state of HIPEC therapy in peritoneal carcinomatosis of colorectal origin.

    Article  PubMed  Google Scholar 

  5. Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21:3737–43.

    Article  PubMed  Google Scholar 

  6. Jayne DG, Fook S, Loi C, Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2002;89:1545–50.

    Article  CAS  PubMed  Google Scholar 

  7. Franko J, Shi Q, Goldman C, Pockage B, Nelson G, Goldberg R, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol. 2012;30:263–7.

    Article  PubMed Central  PubMed  Google Scholar 

  8. Klaver Y, Simkens L, Lemmens V, Koopman M, Teerenstra S, Biechrodt R, et al. Outcomes of colorectal patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy. EJSO. 2012;38:617–23.

    Article  CAS  PubMed  Google Scholar 

  9. Hompes D, Boot H, Van Tinteren H, et al. Unresectable peritoneal carcinomatosis from colorectal cancer: a single center experience. J Surg Oncol. 2011;104:269–73.

    Article  PubMed  Google Scholar 

  10. Mulsow J, Merkel S, Agaimy A, et al. Outcomes following surgery for colorectal cancer with synchronous peritoneal metastases. Br J Surg. 2011;98:1785–91.

    Article  CAS  PubMed  Google Scholar 

  11. van de Vaart P, van der Vange N, Zoetmulder F, et al. Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. Eur J Cancer. 1998;34:148–54.

    Article  PubMed  Google Scholar 

  12. Jacquet P, Sugarbaker PH. Peritoneal-plasma barrier. In: Sugarbaker PH, editor. Peritoneal carcinomatosis: principles of management. Boston: Kluwer Academic Publishers; 1996. p. 53–63.

    Chapter  Google Scholar 

  13. Dedrick RL, Myers CE, Bungay PM, DeVita Jr VT. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep. 1978;62(1):1–11.

    CAS  PubMed  Google Scholar 

  14. van Ruth S, Verwaal VJ, Zoetmulder FAN. Pharmacokinetics of intraperitoneal mitomycin C. Surg Oncol Clin N Am. 2003;12:771–80.

    Article  PubMed  Google Scholar 

  15. Rietbroeck RC, van de Vaart PJ, Haveman J, Blommaert FA, Geerdink A, Bakker PJ, et al. Hyperthermia enhances the cytotoxicity and platinum-DNA adducts formation of lobaplatin and oxaliplatin in cultured SW 1573 cells. J Cancer Res Clin Oncol. 1997;123:6–12.

    Article  Google Scholar 

  16. Dickson JA. Hyperthermia and laboratory animal systems, Proc. Intern. Symp. On cancer therapy by hyperthermia and radiation. Washington, DC: Am. Coll. Rad; 1975. p. 105–6.

    Google Scholar 

  17. Piché N, Leblond FA, Sidéris L, et al. Rationale for heating oxaliplatin for the intraperitoneal treatment of peritoneal carcinomatosis: a study of the effect of heat on intraperitoneal oxaliplatin using a murine model. Ann Surg. 2011;254(1):138–44.

    Article  PubMed  Google Scholar 

  18. Becouarn Y, Ychou M, Ducreux M, Borel C, Bertheault-Cvitkovic F, Seitz JF, et al. Phase II trial of oxaliplatin as first line chemotherapy in metastatic colorectal cancer. J Clin Oncol. 1998;16:2739–44.

    CAS  PubMed  Google Scholar 

  19. Giachetti S, Perpoint B, Zidani R, Le Bail R, Faggiuolo R, Focan C, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomoduled fluorouracil-leucovorin as first line treatment of metastatic colorectal cancer. J Clin Oncol. 2000;18:136–47.

    Google Scholar 

  20. De Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938–47.

    PubMed  Google Scholar 

  21. Hompes D, D’Hoore A, Wolthuis A, Fieuws S, Mirck B, Bruin S, Verwaal V. The use of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: A comparative study. J Surg Oncol. 2013.

  22. Glockzin G, von Breitenbuch P, Schlitt HJ, Piso P. Treatment-related morbidity and toxicity of CRS and oxaliplatin-based HIPEC compared to a mitomycin and doxorubicin-based HIPEC protocol in patients with peritoneal carcinomatosis: a matched-pair analysis. J Surg Oncol. 2013;107(6):574–8.

    Article  CAS  PubMed  Google Scholar 

  23. Votanopoulos K, Ihemelandu C, Shen P, Stewart J, Russell G, Levine EA. A comparison of hematologic toxicity profiles after heated intraperitoneal chemotherapy with oxaliplatin and mitomycin C. J Surg Res. 2013;179(1):e133–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  24. Armour EZP, McEachern D, Wang G, et al. Sensitivity of human cells to mild hyperthermia. Cancer Res. 1993;53:2740–4.

    CAS  PubMed  Google Scholar 

  25. Overgaard J. Effect of hyperthermia on malignant cells in-vivo, a review and hypothesis. Cancer. 1977;39:2637–46.

    Article  CAS  PubMed  Google Scholar 

  26. Elias D, Antoun S, Goharin A, et al. Research on the best chemohyperthermia technique for treatment of peritoneal carcinomatosis after complete resection. Int J Surg Invest. 2000;1:431–9.

    CAS  Google Scholar 

  27. Koga S, Hamazoe R, Maeta M, et al. Treatment of implanted peritoneal cancer in rats by continuous hyperthermic peritoneal perfusion in combination with an anticancer drug. Cancer Res. 1984;44:1840–2.

    CAS  PubMed  Google Scholar 

  28. Pelz J, Doerfer J, Dimmler A, et al. Histological response of peritoneal carcinomatosis after hyperthermic intraperitoneal chemoperfusion in experimental investigations. BMC Cancer. 2006;2:162–9.

    Article  Google Scholar 

  29. Elias D, Glehen O, Pocard M, et al. A comparative study of complete cytoreductive surgery plus intraperitoneal chemotherapy to treat peritoneal dissemination from colon, rectum, small bowel, and nonpseudomyxoma appendix. Ann Surg. 2010;251:896–901.

    Article  PubMed  Google Scholar 

  30. Cavaliere F, De Simone M, Virzi S, et al. Prognostic factors and oncologic outcome in 146 patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy: Italian multicenter study S.I.T.I.L.O. Eur J Surg Oncol. 2011;37:148–54.

    Article  CAS  PubMed  Google Scholar 

  31. Hansson J, Graf W, Pahlman L, et al. Postoperative adverse events and long-term survival after cytoreductive surgery and intraperitoneal chemotherapy. Eur J Surg Oncol. 2009;35:202–8.

    Article  CAS  PubMed  Google Scholar 

  32. Mahteme H, Hansson J, Berglund A, et al. Improved survival in patients with peritoneal metastases from colorectal cancer: a preliminary study. Br J Cancer. 2004;90:403–7.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  33. Tempany CM, Zou KH, Silverman SG, et al. Staging of advanced ovarian cancer: comparison of imaging modalities-report from radiological diagnostic oncology group. Radiology. 2000;215:761–7.

    Article  CAS  PubMed  Google Scholar 

  34. Jacquet P, Jelinek JS, Steves AM, Sugarbaker PH. Evaluation of computed tomography in patients with peritoneal carcinomatosis. Cancer. 1993;72:1631–6.

    Article  CAS  PubMed  Google Scholar 

  35. Davies J, Chalmers AG, Sue-Ling HM, et al. Spiral computed tomography and operative staging of gastric carcinoma: a comparison with histopathological staging. Gut. 1997;41:314–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  36. de Bree E, Koops W, Kröger R, et al. Peritoneal carcinomatosis from colorectal origin: correlation of preoperative CT with intraoperative findings and evaluation of interobserver agreement. J Surg Oncol. 2004;86:64–73.

    Article  PubMed  Google Scholar 

  37. Koh JL, Yan TD, Glenn D, Morris DL. Evaluation of preoperative computed tomography in estimating peritoneal cancer index in colorectal peritoneal carcinomatosis. Ann Surg Oncol. 2009;16:327–33.

    Article  PubMed  Google Scholar 

  38. Esquivel J, Chua TC, Stojadinovic A, et al. Accuracy and clinical relevance of computed tomography scan. interpretation of peritoneal cancer index in colorectal cancer peritoneal carcinomatosis: a multi-institutional study. JSO. 2010;102:565–70.

    Article  CAS  Google Scholar 

  39. Tanaka T, Kawai Y, Kanai M, et al. Usefulness of FDG-positron emission tomography in diagnosing peritoneal recurrence of colorectal cancer. Am J Surg. 2002;184(5):433–6.

    Article  PubMed  Google Scholar 

  40. Bamba Y, Itabashi M, Kameoka S. Clinical use of PET/CT in peritoneal carcinomatosis from colorectal cancer. Hepatogastroenterology. 2012;59(117):1408–11.

    PubMed  Google Scholar 

  41. Iversen LH, Rasmussen PC, Laurberg S. Value of laparoscopy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis. Br J Surg. 2013;100(2):285–92.

    Article  CAS  PubMed  Google Scholar 

  42. Pomel C, Appleyard TL, Gouy S, et al. The role of laparoscopy to evaluate candidates for complete cytoreduction of peritoneal carcinomatosis and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol. 2005;31(5):540–3.

    Article  CAS  PubMed  Google Scholar 

  43. Chua TC, Morris DL, Esquivel J. Impact of the peritoneal surface disease severity score on survival in patients with colorectal cancer peritoneal carcinomatosis undergoing complete cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2010;17:1330–6.

    Article  PubMed  Google Scholar 

  44. Verwaal VJ, van Tinteren H, van Ruth S, Zoetmulder FAN. Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy. Br J Surg. 2004;91:739–46.

    Article  CAS  PubMed  Google Scholar 

  45. Cashin PH, Graf W, Nygren P, Mahteme H. Patient selection for cytoreductive surgery in colorectal peritoneal carcinomatosis using serum tumor markers: an observational cohort study. Ann Surg. 2012;256:1078–83. This article describes the COREP score, the first prognostic evaluation that can be used preoperatively. This new score based on tumor markers incorporates the factor of tumor response to chemotherapy. Its independence from an evaluation PC is a major advantage in clinical practice.

    Article  PubMed  Google Scholar 

  46. Cashin PH, Graf W, Nygren P, Mahteme H. Comparison of prognostic scores for patients with colorectal cancer peritoneal metastases treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2013;20:4183–9. Aside from being the first preoperative prognostic score, the COREP seems to be more accurate than previously described scores. This article calls for broad use and evaluation of this promising prognostic tool.

    Article  PubMed  Google Scholar 

  47. Gervais MK, Dubé P, McConnell Y, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis arising from colorectal cancer. J Surg Oncol. 2013;108(7):438–43.

    Article  CAS  PubMed  Google Scholar 

  48. Kuijpers AM, Mirck B, Aalbers AG, et al. Cytoreduction and HIPEC in Netherlands: nationwide long-term outcome following the Dutch protocol. Ann Surg Oncol. 2013;20(13):4224–30.

    Article  PubMed Central  PubMed  Google Scholar 

  49. Verwaal VJ, Bruin S, Boot H, et al. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15(9):2426–32.

    Article  PubMed  Google Scholar 

  50. Elias D, Lefebre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009;27(5):681–5.

    Article  PubMed  Google Scholar 

  51. da Silva RG, Sugarbaker PH. Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer. J Am Coll Surg. 2006;203(6):878–86.

    Article  PubMed  Google Scholar 

  52. Quenet F, Goéré D, Mehta SS, et al. Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis. Ann Surg. 2011;254:294–301.

    Article  PubMed  Google Scholar 

  53. Elias D, Faron M, Stan luga B et al. Prognostic similarities and differences in optimally resected liver metastases and peritoneal metastases from colorectal cancers. Ann Surg. 2014. This article illustrates that colorectal peritoneal carcinomatosis can be treated with CCRS plus HIPEC as, or even more, efficiently than liver metastases can be treated by liver resection.

  54. Goéré D, Malka D, Tzanis D, et al. Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy? Ann Surg. 2013;257(6):1065–71.

    Article  PubMed  Google Scholar 

  55. Maggiori L, Goére D, Viana B, et al. Should patients with peritoneal carcinomatosis of colorectal origin with synchronous liver metastases be treated with a curative intent? Ann Surg. 2013;258:116–21. This study reinforces the idea that metastatic disease should be addressed by evaluating tumor load rather than separated metastatic sites.

    Article  PubMed  Google Scholar 

  56. Elias D, Faron M, Goéré D, et al. A simple tumor load-based nomogram for surgery in patients with colorectal liver and peritoneal metastases. Ann Surg Oncol. 2014.

  57. Elias D, Goéré D, Di Pietrantonio D, et al. Results of systematic second-look surgery in patients at high risk of developing colorectal peritoneal carcinomatosis. Ann Surg. 2008;247(3):445–50.

    Article  PubMed  Google Scholar 

  58. Honoré C, Goéré D, Souadka A, et al. Definition of patients presenting a high risk of developing peritoneal carcinomatosis after curative surgery for colorectal cancer: a systematic review. Ann Surg Oncol. 2013;20:183–92.

    Article  PubMed  Google Scholar 

  59. Élias D, Honoré C, Dumont F, et al. Results of systematic second-look surgery plus HIPEC in asymptomatic patients presenting a high risk of developing colorectal peritoneal carcinomatosis. Ann Surg. 2011;254:289–93. This article was instrumental in the development of the second-look surgery concept in PC. It helped set the basis of this emerging and promising approach by quantifying the incidence of PC recurrence in high-risk patients. Furthermore, it illustrated the effect early detection and treatment of this disease with second-look surgery and HIPEC can have on disease-free and overall survival.

    Article  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Dominique Élias, Alexis-Simon Cloutier, Fabrizio Vittadello, Charles Honoré, Frédéric Dumont, and Diane Goéré declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Département de Chirurgie Oncologique, Gustave Roussy, Cancer Campus, Grand Paris, Rue Camille Desmoulins, 94805, Villejuif, Cedex, France

    Dominique Élias, Alexis-Simon Cloutier, Fabrizio Vittadello, Charles Honoré, Frédéric Dumont & Diane Goéré

Authors
  1. Dominique Élias
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alexis-Simon Cloutier
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fabrizio Vittadello
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Charles Honoré
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Frédéric Dumont
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Diane Goéré
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dominique Élias.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Élias, D., Cloutier, AS., Vittadello, F. et al. Adjuvant HIPEC in Colorectal Cancer. Curr Colorectal Cancer Rep 10, 313–320 (2014). https://doi.org/10.1007/s11888-014-0224-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11888-014-0224-7

Keywords

Search

Navigation